EGFR and cancer: To dissect the relative contribution of each pathway to resistance against anti-EGFR therapy, we stably expressed a ΔRAF-1/ERTam- or a myristoylated-AKT/ERTam (myr-AKT/ERTam) construct in RAS wild type A431 and Difi cancer cell lines.